CDT Equity Inc. SAFE Investment in Pep'd Inc.
August 25, 2026
CDT Equity Inc. entered into a SAFE note with Pep'd Inc. to expand its exposure to the growing US peptide market. The SAFE is expected to convert into Safe Preferred Stock upon Pep'd closing an equity financing, using a $10,000,000 valuation cap.
- Buyers
- CDT Equity Inc.
- Targets
- Pep'd Inc.
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
&Capital Launches SafetyCo Partners and Makes Initial Investment in Safety Design Strategies
November 22, 2022
Professional Services
Private equity firm &Capital launched SafetyCo Partners, a health & safety services platform, and announced an initial investment / partnership with Safety Design Strategies (SDS). The deal brings SDS into the SafetyCo platform to accelerate growth, integrate services (consulting, training, rescue, inspection) and consolidate a fragmented Canadian safety services market.
-
Nordic Capital Becomes Major Shareholder in Equashield
October 7, 2022
Medical Devices
Nordic Capital has made a significant minority investment in Equashield to support the company's next phase of growth and global expansion. The partnership will help Equashield commercialize its automated compounding systems and scale its closed system transfer device (CSTD) business across healthcare markets.
-
Biosynth Carbosynth Acquires Pepscan
July 4, 2022
Biotechnology
Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.
-
Vesey Street Capital Recapitalizes Safecor Health
August 25, 2021
Healthcare Services
Funds managed by Vesey Street Capital Partners completed a recapitalization of Safecor Health, the national leader in pharmaceutical unit-dose packaging services for hospitals, health systems, manufacturers and digital pharmacy companies. The recapitalization (terms undisclosed) is intended to support Safecor's growth, investment in capabilities and expansion via add-on acquisitions; JP Morgan provided debt financing.
-
Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide
December 16, 2019
Biotechnology
Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.
-
Ampersand Capital Partners Majority Recapitalizes New England Peptide
October 7, 2019
Biotechnology
Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.